In another randomized phase 3 trial involving adults with Ph-negative R/R B-cell precursor ALL (12), treatment with blinatumomab, a bi-specific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive ALL blasts, resulted in significantly longer overall survival (OS) than standard chemotherapy. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.